论文部分内容阅读
目的:探讨心可舒对冠心病并室性早搏患者心率变异性、QT离散度的影响及其临床效果。方法:将60例频发早搏患者随机分成治疗组(30例)和对照组(30例)。在常规治疗的基础上治疗组口服心可舒4片/次,3次/日。观察4~12周,并在服药前及服药后各行1次动态心电图及普通心电图检查,对比观察其服药前后心率变异性、QT离散度等电生理参数及临床指标变化,并评价其疗效。结果:(1)两组治疗室性早搏均有效,但是心可舒组总有效率高于对照组总有效率,差异有统计学意义(P(0.05)。(2)心可舒组治疗后心率变异性指标SDNN、SDANN以及HF较治疗前均上升,LF下降,差异有统计学意义(P(0.05);治疗后心可舒组心率变异性指标SDNN、SDANN以及HF较对照组均上升,LF下降,差异有统计学意义(P(0.05)。(3)心可舒组治疗后QTd及QTcd较治疗前均下降,差异有统计学意义(P(0.05);治疗后心可舒组QTd及QTcd较对照组均下降,差异有统计学意义(P(0.05)。结论:心可舒治疗冠心病并室性早搏疗效显著,对心脏自主神经功能活动有明显改善作用。
Objective: To investigate the effect of Xinkeshu on heart rate variability and QT dispersion in patients with coronary heart disease complicated with premature ventricular contractions and its clinical effect. Methods: Sixty patients with frequent premature beats were randomly divided into treatment group (30 cases) and control group (30 cases). On the basis of conventional treatment, the treatment group was treated with 4 tablets of xeroxone and 3 times / day. Observed 4 to 12 weeks, and before taking the medication and after taking a line of Holter and ECG 1 times before and after its administration heart rate variability, QT dispersion and other electrophysiological parameters and clinical indicators of change, and evaluate its efficacy. Results: (1) Both groups were effective in treating ventricular premature beats, but the total effective rate in XK group was higher than that in the control group (P <0.05). (2) The indexes of heart rate variability (SDNN, SDANN and HF) were higher than those before treatment and LF was decreased, the difference was statistically significant (P (0.05)). After treatment, the indexes of heart rate variability (SDNN, SDANN and HF) (P <0.05). (3) The QTd and QTcd in XK group were significantly lower than those before treatment (P <0.05), and the QTd And QTcd were significantly lower than those in the control group (P <0.05) .Conclusion: XKK treatment of coronary heart disease and ventricular premature beats significantly effect on cardiac autonomic nervous activity was significantly improved.